What do you know about the chemistry active solution liraglutide intermediates?

As we all know, in the pharmaceutical industry, the production of preparations needs to be supported by the API links upstream of the industry chain. It can be seen that the large demand for liraglutide injection will inevitably drive the growth of the demand for its APIs. The liraglutide bulk drug market will be greatly expanded.

What is the necessity for the existence of chemistry active solution liraglutide intermediates?

What is the working principle of chemistry active solution liraglutide intermediates?

What are the current problems in the production of liraglutide?

What is the necessity for the existence of chemistry active solution liraglutide intermediates?

Diabetes is a common and frequently occurring disease in modern society, and its pathogenesis is complicated. Modern medicine believes that diabetes requires long-term or lifelong medication. In the current diabetes treatment environment, traditional methods only require that hypoglycemic drugs have no cardiovascular risk, and there are no special requirements for curative effects. The situation of "lowering blood sugar but not curing the disease" is common. Taking China as an example, among diabetic patients, it is estimated that 60% of the patients have not been diagnosed, 23% have not received treatment, 11% have not achieved the effect, and only 6% have achieved the expected effect. The incidence of diabetic urine is high but the diagnosis and treatment rate is very Low. The emergence of chemistry-active solution liraglutide intermediates provides new possibilities for the treatment of diabetes.

What is the working principle of chemistry active solution liraglutide intermediates?

In the family of GLP-1 analogs, liraglutide is a glucagon-like peptide-1 (GLP-1) analog with 97% sequence homology to human GLP-1 and can activate the Human GLP-1 receptor promotes the secretion of insulin by pancreatic cells, which is suitable for adult type II diabetes patients to control blood sugar. In addition to treating type 1 diabetes, liraglutide was approved by the US FDA in December 2014 as a treatment for obesity, further promoting the sales of liraglutide.

What are the current problems in the production of liraglutide?

1. The production of liraglutide can be done through genetic engineering, but because liraglutide is a non-natural active polypeptide with branched-chain modification, the production technology is extremely difficult, the equipment requirements are high, the large-scale production risk is high, and the cost is high, is not conducive to industrial production.

2. liraglutide can also be produced through solid-liquid synthesis, which requires several different stages such as solid-phase synthesis of fragments, fully protected cleavage, fully protected fragments purification, and fragment condensation. The production cycle is long. At the same time, since the liraglutide fragment is a fully protected polypeptide and is very hydrophobic, it greatly increases the difficulty of purification. This brings about the problems of a long cycle and high cost for large-scale production.

From the above, we can see that there are some difficulties in the production process of liraglutide, but the effect of liraglutide is very powerful, causing the market for liraglutide to continue to expand. Chengdu Pukang Company is a company that focuses on the production of chemistry active solution liraglutide intermediates and is committed to providing high-purity chemistry active solution liraglutide intermediates. For customers in need, you can choose them with complete confidence.